US Bancorp’s Kronos Bio KRON Stock Holding History

US Bancorp’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,634	Closed	-$19K	–	4146
2022 Q1	$19K	Buy	2,634 +2,372	+905%	+$20.2K	﹤0.01%	3104
2021 Q4	$4K	Buy	262 +182	+228%	+$2.85K	﹤0.01%	3720
2021 Q3	$2K	Buy	+80	New	+$1.72K	﹤0.01%	3889

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

US Bancorp's KRON Position: Q2 2022 in Review

US Bancorp sold out of Kronos Bio (KRON) in Q2 2022, closing a stake of 2,634 shares — an estimated $19K sold.

US Bancorp first reported a position in KRON in Q3 2021 and held it in 3 quarters. The position peaked at $19K in Q1 2022. 93 funds tracked by Wall St. Rank hold KRON as of Q2 2022.

US Bancorp reported no remaining Kronos Bio position as of Q2 2022 after selling out during the quarter.
US Bancorp sold 2,634 Kronos Bio shares in Q2 2022, an estimated $19K.
US Bancorp first reported a position in Kronos Bio in Q3 2021 and held it in 3 quarters.
US Bancorp's Kronos Bio position peaked at $19K in Q1 2022.
93 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.